Back to search results

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Abroad (travel likely)RecruitingPHASE4

Conditions

Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · Metastatic Castration-resistant Prostate Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Heather Jacene, MD) · hjacene@partners.org · 617-632-3767
    Contact: Principal Investigator (Heather Jacene, MD)

  • Brigham and Womens Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Heather A Jacene, MD) · hjacene@partners.org · 617 632-3767
    Contact: Principal Investigator (Heather A Jacene, MD)
Study leads

  • Heather Jacene, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)